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This is a weekly summary of the daily COVID-19 health evidence summary (HES) which are based 
on 3 hours of desk-based research each day. The summary is not intended to be a comprehensive 
summary of available evidence on COVID-19 but aims to make original documents easily 
accessible to decision makers which, if relevant to them, they should go to before making 
decisions. 






01.06.2020 COVID-19 mortality 
is associated with 
pre-existing 




| Article  
 Cross-sectional 
study of 45 HICs 
and 42 non-HICs 
using global burden 
of disease data  







disease burdens and 




02.06.2020 Clinical features of 
COVID-19 patients 








 The majority of 
COVID-19 patients 
are male. COVID-19 
comorbidities were 
found in several 
patients. The main 
clinical symptoms of 
COVID-19 in this 
study were cough, 
sore throat, and 
fever.  
 The abnormal 




is anemia, an 
increase in AST and 
ALT levels, and 
chest x-ray images 
of pneumonia. All 
patients are in mild 
condition. The 
average length of 
hospital admission 
patients to discharge 
is more than 30 
days.  
 The inability of a 
local laboratory to 
check for positive 
confirmation of 
COVID-19 makes 
the admission period 
of the patient in the 
hospital very long. 
The availability of 












in the age of 
coronavirus 





 MERS-CoV and 
SARS-CoV-1 are 
known to cause 




 The pulmonary 
manifestations of 
C19 have been well 
described in the 
literature but 
emerging evidence 










with C19  which may 
lead to improved 








further studies are 
required  










The Lancet | 
Article 
 Analysis of 1128 
patients who had 
surgery between 1 





in half of patients 
with perioperative 
SARS-CoV-2 
infection and are 
associated with high 
mortality 
 Thresholds for 
surgery during the 
C19 pandemic 
should be raised 
compared to normal 
practice, especially 
in men aged 70 





to delay or avoid the 
need for surgery 
should be 
considered  







severity in patients 
with cancer in 







 Patients with cancer 
and COVID-19 were 
more likely to 
deteriorate into 
severe illness than 
those without cancer 
 Risk factors 
identified in this 
study may help early 
clinical surveillance 
of disease 
progression of C19 







outcomes, and risk 
factors for mortality 
in patients with 
cancer and COVID-







 Patients with cancer 
and COVID-19 
admitted to hospital 
had a high case-





4 weeks before 
symptom onset and 
male sex, may help 
clinicians identify 
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 It is likely that 40 















than 14 days 
 Absence of 
symptoms in 
infected persons 
might not imply 
absence of harm. 















 Limitation – most 
data under review 
was from cohort 
studies 

























 This study 
assesses the 





19 in the UK. 






shielding of people 









would need to be 
in place for a large 
proportion of the 

















 statistical analysis 
for understanding 
the effect of the 
environmental 
temperature on the 
exponential growth 
rate of the cases 
infected by 
COVID-19 for US 







 The results clearly 
support the first 
reported statistically 
significant relationship 
of negative correlation 























 A molecular 
epidemiological study 
by a network of 
government and 
university laboratories 
of the first 21 SARS-
CoV-2 whole genomes 
sampled in the first 
port of entry, KwaZulu-
Natal (KZN) during the 
first month of the 
epidemic 
 The early introduction 
of SARS-CoV-2 in 
KZN included a 
localised hospital 
outbreak which may 
explain the initially 
high death rates in the 
province 
 The current high rate 
of transmission of C19 
in the Western Cape 
and Eastern Cape 




















and reuse and 












N95 reuse and 
extended use 
during critical PPE 
shortages. This 
study examined the 
prevalence of N95 
fit test failure while 
reusing 2 common 
types of N95 masks 
 Duckbill N95s had 
a high failure rate. 
Failure of dome-
shaped masks was 
associated with 
increased use.  
 N95 failure may 
contribute to SARS-
CoV-2 transmission 




evaluate N95 fit 
during extended 
use or reuse and 
limit duckbill mask 











































 The effectiveness of 
3 distancing 
strategies designed 
to keep the curve flat 
and aid compliance 
post-lockdown are 
evaluated in this 
study 
 Strategic social 
network-based 
reduction of contact 
strongly enhances 
the effectiveness of 
social distancing 
measures while 






in Hong Kong 











 Control measures 
implemented in 





CoV-2 as of May 
2020 
 Relatively low 
seroprevalence 
suggests lack of 
herd immunity and 
susceptibility to a 
resurgence of the 
SARS-CoV-2 
epidemic if public 
health measures 
are relaxed 
 Although a small 
study size, provides 
a baseline for public 
health authorities 
when evaluating the 



















 Systematic review 





transmission and to 
assess the use of 
face masks and eye 
protection to prevent 















distancing of 1 m or 
more and provide 
quantitative 
estimates for models 
and contact tracing 
to inform policy.  
 Optimum use of face 
masks, respirators, 
and eye protection 
in public and health-
care settings should 
be informed by 
these findings and 
contextual factors.  
 Robust randomised 
trials are needed to 
better inform the 































 Discusses key use 
cases for SARS-
CoV-2 antibody 
detection tests and 
their application to 
serologic studies 
 Reviews currently 
available assays 
 Highlights ongoing 
research 
 Proposes potential 
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 A randomised, double-
blind, placebo-controlled 
trial across the US and 




 Hydroxychloroquine did 
not prevent illness 
compatible with C19 or 
confirmed infection when 
used within 4 days after 
high-risk or moderate-




03.06.2020 Effect of 
convalescent 
plasma therapy 











 In this randomised 
clinical trial of 103 
patients in China that 
was terminated early 
(underpowering the 
study), among patients 
with severe or life-
threatening C19, 
convalescent plasma 
therapy added to 
standard treatment did 
not significantly improve 
the time to clinical 





















roquine have been 
proposed as potential 
treatments for COVID-
19. These drugs have 




deficiency. Analysis of 
whole-genome sequence 
data of 458 individuals 
from sub-Saharan Africa 






variation across the 
continent. 
 The high prevalence of 
variants in the G6PD 
gene found in this 
analysis suggests that it 
may be a significant 
interaction factor in 
clinical trials of 
chloroquine and 
hydrochloroquine for 
treatment of COVID-19 in 
Africans. 


















 A survey run by WHO with 
responses from 155 
countries has shown that 
C19 significantly impacts 
health services for cancer, 
cardiovascular disease and 
diabetes 
 Countries must find 
innovative ways to continue 






















 Pakistani residents had 
good knowledge and 
practices towards COVID-
19 yet there are gaps in 
specific aspects of 
knowledge, and practice 
that should be focused in 
future awareness and 
educational campaigns.  
 Study recommends the 
ministry of health 
authorities promote all 
precautionary and 
preventive measures of 
COVID-19 - to all strata of 
equity 
12 
society including less 
privileged people, older 















 From 26th to 29th March 
an online survey 
 1106 responses from 
around 64 cities in the 
country 
 During the initial stages of 
COVID-19 in India, almost 
one-third respondents had 
a significant psychological 
impact. This indicates a 
need for more systematic 
and longitudinal 
assessment of 
psychological needs of the 
population, which can help 
the government in 
formulating holistic 
interventions for affected 
individuals. 











 Research suggests that 
behavioural health 
concerns should take a 
primary role in response to 
the pandemic 
 A four-step services 
system is proposed 
designed for 
implementation with a 
variety of different groups 
and reserves limited 
clinical services for the 















 Study to understand the 
public perception of 
socioeconomic crises 
and human stress in 
resource-limited 
settings of Bangladesh 
during the C19 
outbreak 






Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
05.06.2020 Oxford University’s COVID-19 
vaccine: next steps towards 
broad and equitable global 
access 
University of Oxford 
| News 
  
04.06.2020 Brazilian Health Regulatory 
Agency approves trial of 
Oxford COVID-19 Vaccine 
Med Sci University 
of Oxford | News 
  
05.06.2020 Retraction – 
Hydroxychloroquine or 
chloroquine with or without a 
macrolide for treatment of 
COVID-19: a multinational 
registry analysis 
The Lancet | 
Comment 
Mandeep R Mehra 
Frank Ruschitzka 
Amit N Patel 
04.06.2020 Retraction: Cardiovascular 
disease: drug therapy, and 




Mandeep R Mehra 
Sapan S Desai 
SreyRam Kuy 
Timothy D Henry 
Amit N Patel 
04.06.2020 Making decisions in a COVID-
19 world 
JAMA | Viewpoint Baruch Fischoff 
04.06.2020 Is Nigeria Ready to leave 
lockdown? 








04.06.2020 India’s COVID-19 testing 
capacity must grow by a factor 
of 10: here’s how that can 
happen 





04.06.2020 The indirect health effects of 
COVID-19: lockdown 
measures and service 
provision 
CGD | Blog Lydia Regan 
Y-Ling Chi 
03.06.2020 As global health players pivot 
to COVID-19 responses we 
need coordinated, real-time, 
formative evaluations 




03.06.2020 Hydroxychloroquine for the 
prevention of COVID-19 – 
searching for evidence 






03.06.2020 Africa’s COVID-19 resilience 
must not lead to complacency 
Chatham House | 
Comment 
Dr Knox Chitiyo 
Prof Martin Rupiya 
Pamela Wadi 
03.06.2020 A randomised trial of 
convalescent plasma for 
COVID-19 – potentially hopeful 
signals 
JAMA | Editorial   
03.06.2020 Population serology for SARS-
CoV-2 is essential to regional 
and global preparedness 
The Lancet Microbe 
| Comment 
Huaiyu Tian 
Ottar N Bjornstad 
15 
02.06.2020 Global outbreak research: 







02.06.2020 COVID-19 and essential 






02.06.2020 Of viruses, vaccines, and 
variability: qualitative meaning 
matters  
Trends in Cognitive 
Sciences 
Valerie F. Reyna 
28.05.2020 Covid-19 in humanitarian 
settings: addressing ethics to 
reduce moral distress 
BMJ | Opinion   
02.06.2020 Hydroxychloroquine or 
chloroquine with or without a 
macrolide for treatment of 
COVID-19: a multinational 
registry analysis 
Lancet | Expression 
of concern 
  
June 2020 Initiation of the Global Coalition 
for Radiotherapy during the 
COVID-19 pandemic 
Lancet Oncology | 
Comment 
Pat Price, Shandi E 
Barney 
02.06.2020 Global mental health and 
COVID-19 
Lancet Psychiatry | 
Comment 
Lola Kola 
02.06.2020 The need for privacy with 
public digital contact tracing 
during the COVID-19 
pandemic 
Lancet Digital 
Health | Comment 
Yoshua Bengio, 
Richard Janda et al 
02.06.2020 Thousands of people will help 
scientists to track the long-term 
health effects of the 
coronavirus crisis 
Nature |News   
02.06.2020 A Harm-Reduction Approach 
to Coronavirus Disease 2019 
JAMA Health Forum 
| Insights 
Eric Kutscher, 




26.05.2020 Why Africa struggles to test for 
covid-19 
The Economist | 
News 
  
25.05.2020 Complexity and fragility: 
realising the SDGs in 
The face of Covid-19 
4SD/ brief David Nabarro 
28.305.2020 Research on covid-19 is 
suffering “imperfect incentives 
at every stage” 
BMJ/ Blog Stephen Armstrong 
01.06.2020 Obstacles to COVID-19 control 





01.06.2020 Food insecurity will be the sting 




01.06.2020 COVID-19 effect on mental 
health: patients and workforce 




Adiukwu et al 
01.06.2020 Death threats in Brazil after a 






30.05.2020 Fears of “highly catastrophic” 
COVID-19 spread in Yemen 
Lancet / World 
Report 
Sharmila Devi 
30.05.2020 COVID-19 strains remote 
regions of Peru 
Lancet / World 
Report 
Barbara Fraser 
30.05.2020 COVID-19 in Africa: no room 
for complacency 
Lancet/ Editorial   
01.06.2020 Covid-19 hot spots appear 
across Latin America 
BMJ/ News Owen Dyer 
17 
  Comment on “COVID-19 
Preparedness Within the 
Surgical, Obstetric, and 
Anesthetic Ecosystem in Sub 
Saharan Africa” 
Annals of Surgery/ 
Letter 
Starr, Nichole; 
Weiser, Thomas  
29.05.2020 Facing mental health fallout 
from the coronavirus pandemic 
WHO / News   
01.06.2020 Covid-19 and health: five 
expert views 






May 2020 Towards universal health 
systems in the Covid-19 era: 
opportunities and threats 
ODI | Briefing paper Emma Samman 
29.05.2020 All eyes are on local 
humanitarian responders 
during Covid-19 – now they 
need support 
ODI | Comment John Bryant 
01.06.2020 COVID-19 significantly impacts 
health services for 
noncommunicable diseases 
WHO | News 
release 
  




Salim S. Abdool 
Karim 
29.05.2020 The right to health must guide 
responses to COVID-19 
The Lancet | 
Comment 
Dainius Puras 
Judith Bueno de 
Mesquita 
Luisa Cabal  
Allan Maleche 
18 
Benjamin  Mason 
Meier 
29.05.2020 Lockdown poses new 
challenges for cancer care in 
India 
The Lancet 
Oncology | News 
Dinesh C. Sharma 
29.05.2020 Poor clinical outcomes for 





Liang V Tang 
Yu Hu 
27.05.2020 Tracking the genomic 
footprints of SARS-CoV-2 
transmission 
Cell | Spotlight Tommy Tsan-Yuk 
Lam 
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
05.06.2020 Statement from the 
Chief Investigators 









 At the request of the MHRA the 
independent DMC recommended 
chief investigators review the 
unblinded data on the 
hydroxychloroquine arm of the 
trial 
 No clinical benefit from use of 
hydroxychloroquine in 
hospitalised patients with COVID-
19 
 Participants are no longer to be 
enrolled to the 
hydroxychloroquine arm of the 
RECOVERY trial with immediate 
effect 
 Full results will be made available 










 Note an update to interim 
guidance issues on 25 March 
2020 
 Practical actions that countries 
can take at national, subregional 
and local levels to reorganise and 
safely delivery high-quality 
essential health services in the 
pandemic context 
19 
 Includes sample indicators for 
monitoring essential health 
services  
 Describes considerations when to 
stop and restart services as C19 
transmission recedes and surges 







 Guidelines from LMICs recognise 
the need for supported home and 
community-based care for C19 to 
protect formal healthcare setting 
capacity and to reduce the risk of 
spread in health facilities. 
Moreover, not all will be able to 
access services or may prefer 
home care. 
 The Brief reviews existing 
guidance n home and community-
based care for C19 in different 
contexts, identifies key issues and 
offers recommendations for 
addressing gaps in home and 
community-based care 
01.06.2020 Basic Psychosocial 




 This Guide aims to help orient 
people supporting the COVID-19 
response to integrate 
psychosocial support skills into 
their daily work, thereby making a 
difference to the well-being of 
people they come into contact 
with during the pandemic.  
 The guide advises how to help 
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  Sierra 
Leone 





US NIH  Our World 
in Data: C19 
Testing 




Our World in 
Data 






      
Global 5050 









  US  COVID-19 
Primer 




     NIH 
LitCovid 
 UKCDR       
Information 
is Beautiful 
     WHO 
COVID-19 
Database 
        








              
C19 Resource Hubs 









  Social 
Sciences 
WHO COVID-
19 pandemic  
Africa CDC Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 







  IDA 














































Cochrane  Center for Global 
Development 





















Institute of Public 
Health 
    





Oxford Centre for 
Evidence-based 
Medicine 
    




 HEART     
UNESCO   NEJM  UKRI     
UN WFP   Oxford 
University 
Press 
 Evidence Aid     
GOARN   PLoS  NIH     
EPI-WIN   SAGE 
journals 
IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   Science  Prevent 
Epidemics  
    
Our World in 
Data 
  Springer 
Nature 




  SSRN 
(Preprints)  
      
23 












      
WorldPop           
Flowminder           





    
  
Online learning & events 









Online course 1 hour WHO 
16.06.2020 Africa beyond COVID-
19 
Virtual event 1h 30 
hours 
ODI 
15.06.2020 Poverty monitoring in 
the context of Covid-
19 





Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 





on COVID-19 and 
Development: John 
Nkengasong 
Event   CGD 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 





















Webinar 1 hour WHO & ISQua – Dr 
Shams Syed, Dr Peter 
Lachman, Dr Teri 
Rynolds & Dr Ed Kelley 




5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 











online brief with Dr 
David Nabarro 
Event 1h 4SD 
25 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 




























the Novel Coronavirus 
Online 
learning 




































of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report 
This is a weekly summary of the daily COVID-19 health evidence summary (HES) which are based on 3 hours of 
desk-based research each day. The summary is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to decision 
makers which, if relevant to them, they should go to before making decisions. The HES are not intended to replace 
medical or professional advice and the researcher or the K4D consortium cannot be held responsible for any 
decisions made about COVID-19 on the basis of the HES alone. K4D services are provided by a consortium of 
leading organisations working in international development, led by the Institute of Development Studies (IDS), with 
Education Development Trust, Itad, University of Leeds Nuffield Centre for International Health and Development, 
Liverpool School of Tropical Medicine (LSTM), University of Birmingham International Development Department 
(IDD) and the University of Manchester Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for International 
Development (DFID) and its partners in support of pro-poor programmes. It is licensed for 
non-commercial purposes only. K4D cannot be held responsible for errors, omissions or any 
consequences arising from the use of information contained in this health evidence summary. 
Any views and opinions expressed do not necessarily reflect those of DFID, K4D or any other 
contributing organisation.   
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